Palivizumab — a monoclonal antibody that prevents respiratory syncytial virus, or RSV, in high-risk infants — did not improve long-term outcomes like respiratory function in children with cystic fibrosis.

The AAP does not recommend routine use of palivizumab for RSV prophylaxis in young children with cystic fibrosis (CF). However, the academy recommends that children with evidence of lung disease or nutritional compromise should be considered for the drug.